All About SARMs :)

Gamer2Be08

Gamer2Be08

New member
I am going to tell you how to run an effective S4/Osta SARM run!

Fist off, what are you trying to accomplish, what effects are you after with SARM?

First off is SARM S4:
-Androgenic at any dose
-Mildly Anabolic at doses above 50mg
-Great for strength
-Great for muscle hardness
-Great for enhanced vascularity
-Great for endurance (aerobic or anaerobic)
-Accelerated fat loss above 50mg
-Joint soothing/healing effects
-Half life is 2-4 hours (multiple doses per day is optimal)
-Better if used on a 5on 2off approach to reduce or diminish sides even at above average doses

Sides:
-Yellow tint (person dependent, but usually starts around 75mg and up)
-Loss of night vision (person dependent, but usually starts around 75mg and up)
-Gene transcription (no known gene transcription effects to be reported yet, but the possibility is there tha you could be permanently messed up)
-Possible mild suppression at 60mg and above (person dependent)

Ostarine SARM:
-Lean mass gains (doses as low as 5mg to cause muscle growth)
-Accelerated fat loss (much moreso than S4 and at doses as low as 5mg ED)
-Joint soothing/healing effects
-Half life is 24 hours (one dose per day optimal)
-Can go up to 50mg ED with no known side effects
-Full looking muscle all day long

NO KNOWN SIDES
NO SHUTDOWN


Now that you know a little bit about the two sarms out now out of multiple sarms to come, you can decide on whether you want to bulk, recomp or cut!

On a bulk or recomp I personally would use Osta over S4.
On a cut I would recommend S4 as it has muscle sparring effects. You will retain/increase strength and you will be hard and vascular.

Can I use in PCT??
In-fact, why not stack the two?
Why not do a bridge?
Can you?
YES!

I am bridging my sarms for PCT:
Osta:15/15/15/15/15/15/15
S4:0/0/0/0/50/50/50/50/50/50

That is my general layout now for my PCT!
You can modify, change your dosing and do whatever you want with the compound!

Is a SARM as good as general AAS?
NO

Is a SARM better than any natty product?
YES

A SARM has its palce in the BB/fitness world, and although it is not as good as AAS, comes in close behind!!!


I may update the above whenever I see fit or find out new info, or if I forgot anything!

If any of you guys have any questions, feel free to ask!
 
I am going to tell you how to run an effective S4/Osta SARM run!

Fist off, what are you trying to accomplish, what effects are you after with SARM?

First off is SARM S4:
-Androgenic at any dose
-Mildly Anabolic at doses above 50mg
-Great for strength
-Great for muscle hardness
-Great for enhanced vascularity
-Great for endurance (aerobic or anaerobic)
-Accelerated fat loss above 50mg
-Joint soothing/healing effects
-Half life is 2-4 hours (multiple doses per day is optimal)
-Better if used on a 5on 2off approach to reduce or diminish sides even at above average doses

Sides:
-Yellow tint (person dependent, but usually starts around 75mg and up)
-Loss of night vision (person dependent, but usually starts around 75mg and up)
-Gene transcription (no known gene transcription effects to be reported yet, but the possibility is there tha you could be permanently messed up)
-Possible mild suppression at 60mg and above (person dependent)

Ostarine SARM:
-Lean mass gains (doses as low as 5mg to cause muscle growth)
-Accelerated fat loss (much moreso than S4 and at doses as low as 5mg ED)
-Joint soothing/healing effects
-Half life is 24 hours (one dose per day optimal)
-Can go up to 50mg ED with no known side effects
-Full looking muscle all day long

NO KNOWN SIDES
NO SHUTDOWN


Now that you know a little bit about the two sarms out now out of multiple sarms to come, you can decide on whether you want to bulk, recomp or cut!

On a bulk or recomp I personally would use Osta over S4.
On a cut I would recommend S4 as it has muscle sparring effects. You will retain/increase strength and you will be hard and vascular.

Can I use in PCT??
In-fact, why not stack the two?
Why not do a bridge?
Can you?
YES!

I am bridging my sarms for PCT:
Osta:15/15/15/15/15/15/15
S4:0/0/0/0/50/50/50/50/50/50

That is my general layout now for my PCT!
You can modify, change your dosing and do whatever you want with the compound!

Is a SARM as good as general AAS?
NO

Is a SARM better than any natty product?
YES

A SARM has its palce in the BB/fitness world, and although it is not as good as AAS, comes in close behind!!!


I may update the above whenever I see fit or find out new info, or if I forgot anything!

If any of you guys have any questions, feel free to ask!
 
So Osta and S4 ARE different?

And do you or do you NOT need post cycle therapy (pct) if running them?

Seems like it would be good to run between cycles?
 
i thought there WAS visual side effects.
people where havng trable seeing.
ontop of it beign soo new theres no KNOWN side effects yess, but that doesnt mean there is not side effects.
here are a few quots from people:
"a guy at my gym was using it and had to stop,it made his vision messed up,he said he saw everthing with a yellow haze.and stayed like that for awile after stopping....fuck that!"

"The vendor says the yellow haze clears up reasonably soon after ending treatment.
I just wanna know if the intensity & duration of vision effect is dependant on the dosage level and duration? "

"The most common side effects reported among all subjects in the trial were fatigue, anemia, nausea, and diarrhea."<------- All of which IMO are chemotherapy sides .......
Again no mention of "visual disturbances"....... I guess point being , THERE IS a version of the S-4 out there that has no visual disturbances associated with it."

some info:
GTx and Merck & Co., Inc. are collaborating to develop Ostarine as part of a broader SARMs clinical development program. SARMs are a new class of drugs with the potential to treat musculoskeletal conditions including cancer cachexia and sarcopenia***8211;the loss of skeletal muscle mass resulting in reduced physical strength and ability to perform activities of daily living.

***8220;We are encouraged by results of this Phase II trial in patients with cancer cachexia, where Ostarine showed significant improvements in lean body mass in both treatment cohorts,***8221; said Mitchell S. Steiner, MD, CEO of GTx. ***8220;We look forward to our continued partnership with Merck on the SARM program, and to evaluating the full potential of our lead product candidate Ostarine in conditions such as cancer cachexia, sarcopenia, and other muscle wasting conditions.***8221;

Cancer cachexia is the severe and progressive loss of muscle that occurs in cancer patients and is responsible for at least 20 percent of cancer deaths. An estimated 410,000 patients in the U.S. are diagnosed with cancer cachexia each year. Currently, there are no drugs approved for the treatment of cancer induced muscle loss.

Study Summary

159 cancer patients with non-small cell lung cancer, colorectal cancer, non-Hodgkin***8217;s lymphoma, chronic lymphocytic leukemia, or breast cancer were randomized in the placebo-controlled study at 35 sites in the U.S. and Argentina. Participants received placebo, 1 mg or 3 mg Ostarine once daily for 16 weeks. Average weight loss prior to entry among all subjects was 8.8 percent and patients were allowed to receive standard chemotherapy during the trial. The drop-out rate during the trial was 33 percent, lower than the expected 50 percent rate observed in other cancer supportive care clinical trials.

The study also met the secondary endpoint of muscle function (performance) as measured by a 12-step stair climb test measuring speed and calculating power, with each Ostarine treatment arm demonstrating a statistically significant average decrease in time to completion and average percentage increase in power exerted. The change from baseline in stair climb power in the placebo, 1 mg and 3 mg treatment groups was 0.23 watts (p=0.66 compared to baseline), 8.4 watts (p=0.002) and 10.1 watts (p=0.001), respectively. Statistically significant decreases from baseline in stair climb time were also observed. No improvement in speed or power was observed for the placebo group. There were no improvements in the endpoints of grip strength and gait speed.

The incidence of serious adverse events, deaths and tumor progression were similar among placebo and the treatment cohorts. The most common side effects reported among all subjects in the trial were fatigue, anemia, nausea, and diarrhea.

About Cancer Cachexia

Cancer induced muscle loss occurs in about 50 percent of cancer patients and may lead to loss of protein stores, severe weakness and fatigue, immobility, loss of independence, and an inability to tolerate and respond to cancer treatments. Cancer induced muscle wasting is responsible for at least 20 percent of cancer deaths. There are no drugs currently approved for the treatment of cancer wasting.

About GTx

GTx, Inc., headquartered in Memphis, Tenn., is a biopharmaceutical company dedicated to the discovery, development, and commercialization of small molecules that selectively target hormone pathways to prevent and treat cancer, fractures and bone loss, muscle loss and other serious medical conditions. GTx has completed a pivotal Phase III clinical trial evaluating toremifene citrate, a selective estrogen receptor modulator, or SERM, at an 80 mg dose for the prevention of bone fractures and treatment of other estrogen deficiency side effects of androgen deprivation therapy in men with prostate cancer. GTx has applied for marketing approval in the United States for toremifene 80 mg and, if approved, plans to commercialize toremifene 80 mg in the U.S. GTx is also developing toremifene citrate at a 20 mg dose in a Phase III clinical trial for the prevention of prostate cancer in high risk men with high grade prostatic intraepithelial neoplasia, or PIN. GTx and Ipsen have entered into a development and collaboration agreement for toremifene citrate in all indications except breast cancer for Europe and the Commonwealth of Independent States (CIS). In December 2007, GTx and Merck & Co., Inc. formed a collaboration to discover and develop selective androgen receptor modulators, or SARMs, a new class of drugs with the potential to treat sarcopenia, which is the loss of skeletal muscle mass resulting in reduced physical strength and ability to perform activities of daily living, as well as cancer cachexia (cancer induced muscle loss) and other musculoskeletal wasting conditions. GTx and Merck are evaluating multiple SARM product candidates, including Ostarine***8482; (designated by Merck as MK-2866) and MK-0773 for a variety of musculoskeletal wasting indications including sarcopenia and cancer cachexia. In the second half of 2009, Merck and GTx expect to complete an ongoing Phase II clinical trial evaluating MK-0773 in sarcopenia. GTx also is conducting a Phase I clinical trial evaluating GTx-758, an oral luteinizing hormone inhibitor, for first line treatment of advanced prostate cancer.








just seems iffy.
so be carful.
for me i was offerd it for free to do a log on and I withdrew from that because its too new and mixed studys and visueal issues concern me.
 
S4 Ostra Dif

Gamer2Be08 said:
What ad? This is info.



S4 is androgenic; makes you hard, strong, vascular

Mk 2866 is anabolic; build lean mass quick and drop fat on a dime
Click to expand...

I have a question for Gamer.
I think you have seen my other thread on the SARM I tried ealier and see from your previous post that you know a fair bit about them. I have not been able to confirm if Ostra is actually SARM S22? Do you onow if this is the case.
My guy reckons that his new batch is 3 times as anabolic as Prop and is to be pinned IM straight after training directly into the body part trained with .25ml - .5ml total.

Have you got any more info on this one? In particular the endurance increase aspect? Do you think that like AAS SARMS would increase RBC?
Thanks Bro
 
"On a bulk or recomp I personally would use Osta over S4.

On a cut I would recommend S4 as it has muscle sparring effects. You will retain/increase strength and you will be hard and vascular."


Is this a typo? From most logs I've reviewed it appears most are using S4 for bulking, not cutting.

This stuff has me very interested. I'm in the process of cutting right now, and it looks likes SARMs could be a good fit for me.
 
Number 5 said:
I have a question for Gamer.
I think you have seen my other thread on the SARM I tried ealier and see from your previous post that you know a fair bit about them. I have not been able to confirm if Ostra is actually SARM S22? Do you onow if this is the case.
My guy reckons that his new batch is 3 times as anabolic as Prop and is to be pinned IM straight after training directly into the body part trained with .25ml - .5ml total.

Have you got any more info on this one? In particular the endurance increase aspect? Do you think that like AAS SARMS would increase RBC?
Thanks Bro
Click to expand...

I know you do not inject osta. But it is considered the anabolic sarm out right now. There may be a more anabolic sarm out in the near future, im not sure though. And I do not believe rbc count will increase on sarm
 
Heimerize said:
"On a bulk or recomp I personally would use Osta over S4.

On a cut I would recommend S4 as it has muscle sparring effects. You will retain/increase strength and you will be hard and vascular."


Is this a typo? From most logs I've reviewed it appears most are using S4 for bulking, not cutting.

This stuff has me very interested. I'm in the process of cutting right now, and it looks likes SARMs could be a good fit for me.
Click to expand...

S4 is better used in a cut buddy
 
juced_porkchop said:
i thought there WAS visual side effects.
people where havng trable seeing.
ontop of it beign soo new theres no KNOWN side effects yess, but that doesnt mean there is not side effects.
here are a few quots from people:
"a guy at my gym was using it and had to stop,it made his vision messed up,he said he saw everthing with a yellow haze.and stayed like that for awile after stopping....fuck that!"

"The vendor says the yellow haze clears up reasonably soon after ending treatment.
I just wanna know if the intensity & duration of vision effect is dependant on the dosage level and duration? "

"The most common side effects reported among all subjects in the trial were fatigue, anemia, nausea, and diarrhea."<------- All of which IMO are chemotherapy sides .......
Again no mention of "visual disturbances"....... I guess point being , THERE IS a version of the S-4 out there that has no visual disturbances associated with it."

some info:
GTx and Merck & Co., Inc. are collaborating to develop Ostarine as part of a broader SARMs clinical development program. SARMs are a new class of drugs with the potential to treat musculoskeletal conditions including cancer cachexia and sarcopenia***8211;the loss of skeletal muscle mass resulting in reduced physical strength and ability to perform activities of daily living.

***8220;We are encouraged by results of this Phase II trial in patients with cancer cachexia, where Ostarine showed significant improvements in lean body mass in both treatment cohorts,***8221; said Mitchell S. Steiner, MD, CEO of GTx. ***8220;We look forward to our continued partnership with Merck on the SARM program, and to evaluating the full potential of our lead product candidate Ostarine in conditions such as cancer cachexia, sarcopenia, and other muscle wasting conditions.***8221;

Cancer cachexia is the severe and progressive loss of muscle that occurs in cancer patients and is responsible for at least 20 percent of cancer deaths. An estimated 410,000 patients in the U.S. are diagnosed with cancer cachexia each year. Currently, there are no drugs approved for the treatment of cancer induced muscle loss.

Study Summary

159 cancer patients with non-small cell lung cancer, colorectal cancer, non-Hodgkin***8217;s lymphoma, chronic lymphocytic leukemia, or breast cancer were randomized in the placebo-controlled study at 35 sites in the U.S. and Argentina. Participants received placebo, 1 mg or 3 mg Ostarine once daily for 16 weeks. Average weight loss prior to entry among all subjects was 8.8 percent and patients were allowed to receive standard chemotherapy during the trial. The drop-out rate during the trial was 33 percent, lower than the expected 50 percent rate observed in other cancer supportive care clinical trials.

The study also met the secondary endpoint of muscle function (performance) as measured by a 12-step stair climb test measuring speed and calculating power, with each Ostarine treatment arm demonstrating a statistically significant average decrease in time to completion and average percentage increase in power exerted. The change from baseline in stair climb power in the placebo, 1 mg and 3 mg treatment groups was 0.23 watts (p=0.66 compared to baseline), 8.4 watts (p=0.002) and 10.1 watts (p=0.001), respectively. Statistically significant decreases from baseline in stair climb time were also observed. No improvement in speed or power was observed for the placebo group. There were no improvements in the endpoints of grip strength and gait speed.

The incidence of serious adverse events, deaths and tumor progression were similar among placebo and the treatment cohorts. The most common side effects reported among all subjects in the trial were fatigue, anemia, nausea, and diarrhea.

About Cancer Cachexia

Cancer induced muscle loss occurs in about 50 percent of cancer patients and may lead to loss of protein stores, severe weakness and fatigue, immobility, loss of independence, and an inability to tolerate and respond to cancer treatments. Cancer induced muscle wasting is responsible for at least 20 percent of cancer deaths. There are no drugs currently approved for the treatment of cancer wasting.

About GTx

GTx, Inc., headquartered in Memphis, Tenn., is a biopharmaceutical company dedicated to the discovery, development, and commercialization of small molecules that selectively target hormone pathways to prevent and treat cancer, fractures and bone loss, muscle loss and other serious medical conditions. GTx has completed a pivotal Phase III clinical trial evaluating toremifene citrate, a selective estrogen receptor modulator, or SERM, at an 80 mg dose for the prevention of bone fractures and treatment of other estrogen deficiency side effects of androgen deprivation therapy in men with prostate cancer. GTx has applied for marketing approval in the United States for toremifene 80 mg and, if approved, plans to commercialize toremifene 80 mg in the U.S. GTx is also developing toremifene citrate at a 20 mg dose in a Phase III clinical trial for the prevention of prostate cancer in high risk men with high grade prostatic intraepithelial neoplasia, or PIN. GTx and Ipsen have entered into a development and collaboration agreement for toremifene citrate in all indications except breast cancer for Europe and the Commonwealth of Independent States (CIS). In December 2007, GTx and Merck & Co., Inc. formed a collaboration to discover and develop selective androgen receptor modulators, or SARMs, a new class of drugs with the potential to treat sarcopenia, which is the loss of skeletal muscle mass resulting in reduced physical strength and ability to perform activities of daily living, as well as cancer cachexia (cancer induced muscle loss) and other musculoskeletal wasting conditions. GTx and Merck are evaluating multiple SARM product candidates, including Ostarine***8482; (designated by Merck as MK-2866) and MK-0773 for a variety of musculoskeletal wasting indications including sarcopenia and cancer cachexia. In the second half of 2009, Merck and GTx expect to complete an ongoing Phase II clinical trial evaluating MK-0773 in sarcopenia. GTx also is conducting a Phase I clinical trial evaluating GTx-758, an oral luteinizing hormone inhibitor, for first line treatment of advanced prostate cancer.








just seems iffy.
so be carful.
for me i was offerd it for free to do a log on and I withdrew from that because its too new and mixed studys and visueal issues concern me.
Click to expand...

doesn't seem to have any answers about the negatives JP, which is also IFFY.

Gamer, i say ad because that is what it is. i wouldn't be suprised if you repped for one of the companies.

regardless, it doesn't belong in this forum.
 
You must log in or register to reply here.

Similar threads

M
Women and Steroids - Female AAS Research
Replies
1
Views
3K
LateStart
L
blakey
lgd 4033 one of my all-time favorite sarms
Replies
2
Views
3K
cybrsage
cybrsage
psizzle_8
--NOW INTRODUCING YK-11 to the SarmsSearch.com lineup! MUST READ!!--
Replies
19
Views
2K
cybrsage
cybrsage
anzel
Study on SARM like effect of low tren
Replies
8
Views
4K
tx045
tx045
cybrsage
New GW studies done - spoiler, you do not need to exercise to gain benefits!
Replies
0
Views
1K
cybrsage
cybrsage
Back
Top